What's happened
As of August 1, 2024, significant developments in cancer treatment and COVID-19 management have emerged. The NHS has approved zanubrutinib for blood cancer patients, while NICE has denied access to Enhertu for breast cancer patients. COVID-19 cases are surging in multiple regions, particularly in the US and Japan, driven by new variants.
What's behind the headline?
Impact of New Cancer Treatments
- Zanubrutinib Approval: The NHS's approval of zanubrutinib allows home treatment for marginal zone lymphoma, potentially improving patient quality of life and reducing hospital visits.
- Enhertu Denial: NICE's refusal to approve Enhertu due to cost-effectiveness concerns raises questions about access to life-extending treatments for breast cancer patients, affecting thousands.
COVID-19 Surge
- Rising Cases: The resurgence of COVID-19, particularly in the US and Japan, underscores the ongoing threat of the virus, especially with new variants like KP.3.
- Public Health Response: The CDC's report of high positivity rates and increased hospitalizations indicates a need for renewed public health measures and vaccination efforts.
What the papers say
According to The Independent, the NHS's approval of zanubrutinib is a 'game changer' for blood cancer patients, allowing them to receive treatment at home. In contrast, the Metro highlights the emotional toll on patients like Tracie Townsend-Mills, who expressed despair over NICE's decision to deny Enhertu, feeling it labels patients as 'not cost-effective.' Meanwhile, Sky News reports AstraZeneca's CEO criticizing NICE's methodology, which he argues limits access to innovative treatments. The Guardian's coverage of the COVID-19 situation in Japan emphasizes the urgency of infection control measures as cases rise, reflecting a broader global trend noted by Axios, which reports that 45 states in the US are experiencing increasing COVID-19 cases, primarily driven by new variants.
How we got here
Recent months have seen a focus on innovative cancer treatments and the ongoing challenges posed by COVID-19. The NHS's approval of zanubrutinib marks a significant advancement for blood cancer patients, while the denial of Enhertu highlights ongoing debates about drug pricing and access. Concurrently, new COVID-19 variants are causing rising infection rates globally.
Go deeper
- What are the side effects of zanubrutinib?
- How does NICE determine drug pricing?
- What measures are being taken to combat COVID-19 variants?
Common question
-
What are the new Covid variants causing a surge in infections and hospitalizations?
The emergence of new Covid variants like FLiRT and KP.3 has led to a rise in infections and hospitalizations in the UK. Experts warn that the virus hasn't gone away, and these new variants are contributing to increased infections and hospitalizations. Understanding the characteristics of these variants is crucial in managing the ongoing threat of the virus.
-
What are the key new Covid variants driving the summer surge of infections?
The annual summer surge of COVID-19 infections has begun, fueled by new variants. Understanding the specific variants responsible for this surge is crucial in navigating the current situation. Let's delve into the key new Covid variants driving the rise in infections.
-
Why are CDC advisers recommending fall COVID-19 booster shots for all Americans?
The CDC advisers' recommendation for fall COVID-19 booster shots comes amidst concerns of immunity waning and the emergence of new variants leading to increased infections. Experts are warning about the potential rise in hospitalizations due to COVID-19, emphasizing the importance of continued vigilance and vaccination efforts.
-
Why are CDC advisers recommending fall COVID-19 booster shots for all Americans?
With the ongoing battle against COVID-19, CDC advisers are recommending fall booster shots for all Americans. This recommendation comes amidst a growing summer wave of infections in the UK and the US, emphasizing the importance of vaccination to curb the spread of the virus.
-
How are new variants like FLiRT and KP.3 contributing to the summer Covid wave?
The emergence of new Covid variants, such as FLiRT and KP.3, has led to a resurgence of infections in the UK and the US. Learn more about how these variants are impacting the current summer Covid wave.
-
What are the characteristics of the FLiRT and LB.1 Covid variants?
As new Covid variants FLiRT and LB.1 continue to spread in the UK and US, understanding their characteristics is crucial in assessing their impact on public health. Let's delve into the key features of these variants and how they differ from previous strains.
-
What are the new Covid variants spreading in the UK?
The UK is currently facing the spread of new Covid variants, including FLiRT and LB.1, which are causing concern among health experts. These variants have the potential to evade immunity and increase transmission rates, leading to a rise in infections and hospitalizations. Understanding the impact of these new variants is crucial for public health measures and vaccination strategies.
-
What health concerns are on the rise in the UK this summer?
As summer unfolds, the UK is witnessing a surge in health concerns, including the spread of new Covid variants and whooping cough cases. Stay informed about the latest health updates to protect yourself and your loved ones.
-
What challenges are clinically extremely vulnerable Covid patients facing in accessing treatments?
Clinically extremely vulnerable Covid patients are encountering various difficulties in accessing necessary treatments amidst the ongoing global surge in Covid-19 cases driven by new variants. Understanding these challenges is crucial for ensuring timely and effective care for this vulnerable population.
-
What are the latest developments regarding new Covid variants?
As new Covid variants emerge, concerns are growing about their impact on public health and healthcare systems. With reports of rising cases in countries like Japan and the US, it's crucial to stay informed about the latest developments, treatment options, and how to access care. Below are some common questions people have regarding these new variants and their implications.
-
Why was Enhertu denied by the NHS?
The recent denial of Enhertu, a life-extending drug for breast cancer, by the NHS has raised significant concerns among patients and healthcare advocates. This decision not only affects those in need of this treatment but also highlights broader issues regarding drug access and cost-effectiveness in the UK healthcare system. Below, we explore the implications of this decision and other related questions.
More on these topics
-
The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. It was first identified in December 2019 in Wuhan, China.
-
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northÂwestern coast of the European mainland.
-
The UK Health Security Agency is a government agency in the United Kingdom, responsible since April 2021 for UK-wide public health protection and infectious disease capability, and replacing Public Health England.
-
Mark Edward John Woolhouse FRSE FMedSci OBE is professor of infectious disease epidemiology at the Usher Institute in the College of Medicine and Veterinary Medicine, University of Edinburgh.
-
Japan is an island country of East Asia in the northwest Pacific Ocean. It borders the Sea of Japan to the west and extends from the Sea of Okhotsk in the north to the East China Sea and Taiwan in the south.
-
Joseph Robinette Biden Jr. is an American politician who is the 46th and current president of the United States. A member of the Democratic Party, he served as the 47th vice president from 2009 to 2017 and represented Delaware in the United States Senate
-
The National Health Service is the publicly funded healthcare system in England, and one of the four National Health Service systems in the United Kingdom.